Show simple item record

dc.contributor.authorKalavalapalli, S
dc.contributor.authorReid, H
dc.contributor.authorKane, J
dc.contributor.authorBuckler, H
dc.contributor.authorTrainer, Peter J
dc.contributor.authorHeald, A H
dc.date.accessioned2009-06-30T14:27:24Z
dc.date.available2009-06-30T14:27:24Z
dc.date.issued2007-01
dc.identifier.citationSilent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. 2007, 44 (Pt 1):89-93 Ann. Clin. Biochem.en
dc.identifier.issn0004-5632
dc.identifier.pmid17270100
dc.identifier.doi10.1258/000456307779596075
dc.identifier.urihttp://hdl.handle.net/10541/71979
dc.description.abstractCirculating insulin-like growth factor-1 (IGF-1) is increasingly being used as a screening test and in ongoing monitoring of treated acromegaly. We here present three cases of women (two of whom were on the oestrogen containing contraceptive pill at the time of presentation) who had normal circulating IGF-1 and no overt clinical features of acromegaly at the time of their pituitary surgery. Postoperatively, all were confirmed to have growth hormone excess in keeping with the presence of active somatotroph pituitary adenomas. We suggest that for optimal patient management, formal evaluation of growth hormone status with oral glucose tolerance testing should ideally be performed on all individuals for whom pituitary surgery is planned.
dc.language.isoenen
dc.subject.meshAcromegaly
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshContraceptives, Oral, Hormonal
dc.subject.meshFemale
dc.subject.meshGrowth Hormone
dc.subject.meshGrowth Hormone-Secreting Pituitary Adenoma
dc.subject.meshHumans
dc.subject.meshInsulin-Like Growth Factor I
dc.titleSilent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, University of Manchester, Salford NHS Trust, Salford M6 8HD, UK.en
dc.identifier.journalAnnals of Clinical Biochemistryen
html.description.abstractCirculating insulin-like growth factor-1 (IGF-1) is increasingly being used as a screening test and in ongoing monitoring of treated acromegaly. We here present three cases of women (two of whom were on the oestrogen containing contraceptive pill at the time of presentation) who had normal circulating IGF-1 and no overt clinical features of acromegaly at the time of their pituitary surgery. Postoperatively, all were confirmed to have growth hormone excess in keeping with the presence of active somatotroph pituitary adenomas. We suggest that for optimal patient management, formal evaluation of growth hormone status with oral glucose tolerance testing should ideally be performed on all individuals for whom pituitary surgery is planned.


This item appears in the following Collection(s)

Show simple item record